Recombinant Anti-CD24 antibody [EPR3006(N)] - BSA and Azide free (ab250123)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3006(N)] to CD24 - BSA and Azide free
- Suitable for: WB, IP
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-CD24 antibody [EPR3006(N)] - BSA and Azide free
See all CD24 primary antibodies -
Description
Rabbit monoclonal [EPR3006(N)] to CD24 - BSA and Azide free -
Host species
Rabbit -
Tested applications
Suitable for: WB, IPmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC-P -
Species reactivity
Reacts with: Human
Does not react with: Mouse, Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
General notes
ab250123 is the carrier-free version of ab179821.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Storage buffer
pH: 7.2
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Affinity purified -
Clonality
Monoclonal -
Clone number
EPR3006(N) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab250123 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration. Predicted molecular weight: 8 kDa.
|
|
IP |
Use at an assay dependent concentration.
|
Notes |
---|
WB
Use at an assay dependent concentration. Predicted molecular weight: 8 kDa. |
IP
Use at an assay dependent concentration. |
Target
-
Function
Modulates B-cell activation responses. Signaling could be triggered by the binding of a lectin-like ligand to the CD24 carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. Promotes AG-dependent proliferation of B-cells, and prevents their terminal differentiation into antibody-forming cells. -
Tissue specificity
B-cells. Expressed in a number of B-cell lines including P32/SH and Namalwa. Expressed in erythroleukemia cell and small cell lung carcinoma cell lines. Also expressed on the surface of T-cells. -
Involvement in disease
Genetic variations in CD24 are associated with susceptibility to multiple sclerosis (MS) [MIM:126200]. A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheat, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. Note=Polymorphisms in CD24 may act as a genetic modifier for susceptibility and progression of MS in some populations, perhaps by affecting the efficiency of CD24 expression on the cell surface. -
Sequence similarities
Belongs to the CD24 family. -
Post-translational
modificationsExtensively O-glycosylated. -
Cellular localization
Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 100133941 Human
- Omim: 600074 Human
- SwissProt: P25063 Human
- Unigene: 644105 Human
- Unigene: 721443 Human
-
Alternative names
- CD 24 antibody
- CD24 antibody
- CD24 antigen (small cell lung carcinoma cluster 4 antigen) antibody
see all
Images
-
All lanes : Anti-CD24 antibody [EPR3006(N)] (ab179821) at 1/1000 dilution
Lane 1 : fetal brain lysate
Lane 2 : SH-SY5Y cell lysate
Lane 3 : human oligodendroglioma lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 8 kDaThis data was developed using ab179821, the same antibody clone in a different buffer formulation.
-
This data was developed using ab179821, the same antibody clone in a different buffer formulation.Western blot analysis on immunoprecipitation pellet from (1) SH-SY5Y cell lysate or (2) 1X PBS (negative control) labeling CD24 using ab179821 at 1/10 dilution, and HRP-conjugated anti-rabbit IgG preferentially detecting the non-reduced form of rabbit IgG.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (0)
ab250123 has not yet been referenced specifically in any publications.